Abstract

Calafate berry, an ancient perennial shrub of South America (Chile and Argentina), produces a high antioxidant capacity berry with a high polyphenol (1344.2–6553 mg GAE/100 g d.w.) and anthocyanin (26.5–80 mg C-3-G/100 g d.w.) content. The beneficial effects of calafate berries on human health are related to the anti-inflammatory, hypoglycemic, anticancer, and antioxidant properties that the berries possess, which have been confirmed through evidence to date, primarily from in vitro, ex vivo, and animal studies. Several investigations have shown a relationship between the consumption of calafate and a reduction in the risk of contracting cardiovascular diseases (CVD). This was evident in changes in plasma level biomarkers related to CVD, such as thrombomodulin (?24%), adiponectin (+68%), sE-selectin (?34%), sICAM-1 (?24%) and proMMP-9 (?31%), and changes in the production of OH radicals in plasma (?17%) after calafate intake. Calafate may have an antithrombotic role that supports cardiovascular health by lowering the Atherogenic and Cardiovascular Risk Indices. Various authors indicate delphinidin-3-glucoside (384–386 mg/100 g) as the primary bioactive compound responsible for the beneficial properties of Calafate. Although some studies report calafate’s health benefits, scientific evidence, especially in humans, remains limited. Meanwhile, Chile is working to domesticate and cultivate calafate, aiming to turn it from a wild native berry into a sustainable crop for use in the antioxidants and nutraceuticals industry. The lack of human clinical trials emphasizes the need for future research to validate calafate’s health benefits berry. © 2025 by the authors.